ATA8602001A - Verwendung von polyklonalen immunglobulinen - Google Patents

Verwendung von polyklonalen immunglobulinen

Info

Publication number
ATA8602001A
ATA8602001A AT0086001A AT8602001A ATA8602001A AT A8602001 A ATA8602001 A AT A8602001A AT 0086001 A AT0086001 A AT 0086001A AT 8602001 A AT8602001 A AT 8602001A AT A8602001 A ATA8602001 A AT A8602001A
Authority
AT
Austria
Prior art keywords
immunoglobulines
polyclonal
polyclonal immunoglobulines
Prior art date
Application number
AT0086001A
Other languages
English (en)
Other versions
AT410637B (de
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0086001A priority Critical patent/AT410637B/de
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Priority to SK1466-2003A priority patent/SK14662003A3/sk
Priority to JP2002592964A priority patent/JP2004532261A/ja
Priority to IL15895002A priority patent/IL158950A0/xx
Priority to BR0210239-0A priority patent/BR0210239A/pt
Priority to CA002449026A priority patent/CA2449026A1/en
Priority to CNA028111214A priority patent/CN1512895A/zh
Priority to PL02367835A priority patent/PL367835A1/xx
Priority to PCT/AT2002/000088 priority patent/WO2002096455A2/de
Priority to MXPA03010829A priority patent/MXPA03010829A/es
Priority to AU2002242447A priority patent/AU2002242447B2/en
Priority to HU0400031A priority patent/HUP0400031A3/hu
Priority to US10/478,942 priority patent/US20040151717A1/en
Priority to EP02707990A priority patent/EP1399185A2/de
Priority to CZ20033273A priority patent/CZ20033273A3/cs
Publication of ATA8602001A publication Critical patent/ATA8602001A/de
Application granted granted Critical
Publication of AT410637B publication Critical patent/AT410637B/de
Priority to IL158950A priority patent/IL158950A/en
Priority to NO20035282A priority patent/NO20035282L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT0086001A 2001-06-01 2001-06-01 Verwendung von polyklonalen immunglobulinen AT410637B (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AT0086001A AT410637B (de) 2001-06-01 2001-06-01 Verwendung von polyklonalen immunglobulinen
AU2002242447A AU2002242447B2 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
IL15895002A IL158950A0 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
BR0210239-0A BR0210239A (pt) 2001-06-01 2002-03-19 Uso de imunoglobinas policlonais e vacina
CA002449026A CA2449026A1 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
CNA028111214A CN1512895A (zh) 2001-06-01 2002-03-19 多克隆免疫球蛋白的用途
PL02367835A PL367835A1 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins as vaccine
PCT/AT2002/000088 WO2002096455A2 (de) 2001-06-01 2002-03-19 Verwendung von polyklonalen immunglobulinen als impfstoff
SK1466-2003A SK14662003A3 (sk) 2001-06-01 2002-03-19 Použitie polyklonálnych imunoglobulínov
JP2002592964A JP2004532261A (ja) 2001-06-01 2002-03-19 ポリクローナル免疫グロブリンの使用
HU0400031A HUP0400031A3 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
US10/478,942 US20040151717A1 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins
EP02707990A EP1399185A2 (de) 2001-06-01 2002-03-19 Verwendung von polyklonalen immunglobulinen als impfstoff
CZ20033273A CZ20033273A3 (en) 2001-06-01 2002-03-19 Use of polyclonal immunoglobulins as vaccine
MXPA03010829A MXPA03010829A (es) 2001-06-01 2002-03-19 Uso de inmunoglobulinas policlonales.
IL158950A IL158950A (en) 2001-06-01 2003-11-19 Use of polyclonal immunoglobulins for producing a vaccine
NO20035282A NO20035282L (no) 2001-06-01 2003-11-27 Anvendelse av polyklonale immunglobuliner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0086001A AT410637B (de) 2001-06-01 2001-06-01 Verwendung von polyklonalen immunglobulinen

Publications (2)

Publication Number Publication Date
ATA8602001A true ATA8602001A (de) 2002-11-15
AT410637B AT410637B (de) 2003-06-25

Family

ID=3682339

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0086001A AT410637B (de) 2001-06-01 2001-06-01 Verwendung von polyklonalen immunglobulinen

Country Status (16)

Country Link
US (1) US20040151717A1 (de)
EP (1) EP1399185A2 (de)
JP (1) JP2004532261A (de)
CN (1) CN1512895A (de)
AT (1) AT410637B (de)
AU (1) AU2002242447B2 (de)
BR (1) BR0210239A (de)
CA (1) CA2449026A1 (de)
CZ (1) CZ20033273A3 (de)
HU (1) HUP0400031A3 (de)
IL (2) IL158950A0 (de)
MX (1) MXPA03010829A (de)
NO (1) NO20035282L (de)
PL (1) PL367835A1 (de)
SK (1) SK14662003A3 (de)
WO (1) WO2002096455A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10127712A1 (de) * 2001-06-07 2002-12-19 Torsten Witte Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
WO2005023867A1 (en) * 2003-09-08 2005-03-17 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
RU2748841C2 (ru) * 2014-12-03 2021-05-31 Цсл Беринг Аг Фармацевтический продукт с увеличенной стабильностью, содержащий иммуноглобулины
FR3072880A1 (fr) * 2017-10-30 2019-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Formulation liposomale et son utilisation en therapie anti-tumorale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3340487A1 (de) * 1983-11-09 1985-05-15 Sandoz-Patent-GmbH, 7850 Lörrach Neue therapeutische verwendung
SG46445A1 (en) * 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP2795289B2 (ja) * 1990-09-04 1998-09-10 富士通株式会社 電子機器におけるプリント板ユニットの保持構造
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
AU1538392A (en) * 1991-03-11 1992-10-06 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
US5562902A (en) * 1994-03-14 1996-10-08 Arp Biomed, Inc. Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin
TWI248819B (en) * 1999-09-27 2006-02-11 Arp Biomed Ltd Pharmaceutical composition containing IVIG for use in treating lymphoma
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
WO2001096392A2 (en) * 2000-06-15 2001-12-20 Millennium Pharmaceuticals, Inc. 22109, a novel human thioredoxin family member and uses thereof
AT410636B (de) * 2001-03-23 2003-06-25 Igeneon Krebs Immuntherapie Verfahren zur herstellung eines impfstoffes

Also Published As

Publication number Publication date
AU2002242447B2 (en) 2007-11-08
BR0210239A (pt) 2004-03-30
NO20035282D0 (no) 2003-11-27
WO2002096455A3 (de) 2003-12-24
WO2002096455A2 (de) 2002-12-05
US20040151717A1 (en) 2004-08-05
SK14662003A3 (sk) 2004-05-04
IL158950A (en) 2008-04-13
AT410637B (de) 2003-06-25
CN1512895A (zh) 2004-07-14
JP2004532261A (ja) 2004-10-21
PL367835A1 (en) 2005-03-07
HUP0400031A3 (en) 2006-03-28
CZ20033273A3 (en) 2004-07-14
EP1399185A2 (de) 2004-03-24
CA2449026A1 (en) 2002-12-05
MXPA03010829A (es) 2004-02-17
HUP0400031A2 (hu) 2004-04-28
IL158950A0 (en) 2004-05-12
NO20035282L (no) 2003-11-27

Similar Documents

Publication Publication Date Title
DE50212455D1 (de) Verwendung von Dimerdiolen
DE60236226D1 (de) Verbesserung der Altersweitsichtigkeit
DK1360169T3 (da) Succinatsalt af O-desmethyl-venlafaxin
DE60218660D1 (de) Herstellung von diskreten regionen mit verschlusselementen
DE60037213D1 (de) Verwendung von Reinigungsgas
DE60233399D1 (de) Erzerrung zweiter ordnung
EP1294513A4 (de) Lokalisationsspezifische kovalente biokonjugation von proteinen
DE50012379D1 (de) Verwendung von nanoskaligen antischuppenwirkstoffen
DE02784674T1 (de) Quantifizierung von polypeptiden
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
NO20041968L (no) Anvendelse av cystationin
DE60223962D1 (de) Verwendung Duftstoff zurückhaltender Zusammensetzungen
DE50103536D1 (de) Verwendung von kationischen Zubereitungen
EP1445096A4 (de) Fälschungssichere folie
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
DE50311406D1 (de) Verwendung von Formkörpern
ATA8602001A (de) Verwendung von polyklonalen immunglobulinen
DE60007360D1 (de) Amorphe modifikation von torasemid
ATE272388T1 (de) Verwendung von kationischen zubereitungen
DE60231350D1 (de) Negativ-aufladbares elektrophotographisches Element
DE50203046D1 (de) Verwendung von Esterquats
ATA2152001A (de) Verwendung von selenhältigen präparaten
ATE331956T1 (de) Nachweis von entzündungen
DE60208365D1 (de) Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln
DE60127917D1 (de) Verwendung von gamma-CEHC als Antioxidantien

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
ELJ Ceased due to non-payment of the annual fee